Albert Boerla wins Genesis Prize 2022

Category : Awards Published on: January 22 2022

Share on facebook

The global pharmaceutical giant Pfizer Inc.’s Chairman and Chief Executive, Albert Bourla, has been awarded with the prestigious Genesis Prize 2022 on January 19, 2022.
He has been awarded for his efforts in leading the development of a COVID-19 vaccine (Pfizer–BioNTech COVID-19 vaccine).
The cash prize of this award is $1 million.
The annual prize is awarded to Jewish people who have achieved significant professional success, in recognition of their accomplishments, contributions to humanity, and commitment to Jewish values and/or to the State of Israel.
It is widely referred to as the “Jewish Nobel Prize”.

Gates Foundation and OpenAI launched the $50 million ‘Horizon1000’ initiative to introduce AI-based healthcare services in 1,000 African primary health centres by 2028.
Read More....
Deepinder Goyal resigned as CEO of Eternal Ltd., and Blinkit CEO Albinder Singh Dhindsa was appointed as the new Group CEO.
Read More....
The Election Commission of India launched the ECINET digital platform at IICDEM 2026 in New Delhi.
Read More....
CDS General Anil Chauhan released the Military Quantum Mission Policy Framework to integrate quantum technologies into the Armed Forces.
Read More....
The Government of India notified emission intensity targets for 208 additional industries under the Carbon Credit Trading Scheme.
Read More....
Murali Krishna, son of legendary singer S. Janaki, passed away due to a heart attack on January 22.
Read More....
MSDE signed an MoU with the World Economic Forum to strengthen vocational education and skill development in India.
Read More....
India is celebrating 150 years of ‘Vande Mataram’ with nationwide cultural events and military band performances.
Read More....
Donald Trump filed a $5 billion lawsuit against JPMorgan Chase and its CEO over alleged debanking.
Read More....
India and Namibia agreed to expand cooperation in defence, critical minerals, health, and digital infrastructure.
Read More....